Korean Celltrion Signs Letter Of Intent With U.S. CDC To Develop Rabies Agents
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biopharmaceutical manufacturing company Celltrion signed a letter of intent Jan. 29 with the U.S. Centers for Disease Control to cooperate in the development and production of antibody drugs to fight rabies, a company official said Thursday
You may also be interested in...
Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference
ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application
Biosimilar Launch Strategy: Reinforce Safety Profiles In Asia – BIO Conference
ATLANTA - When organizers titled the "Asia as the Biosimilar Launch Pad" session at BIO, they meant it. Many of the panelists agreed that a good strategy for launching biosimilars in the U.S. is to first release the product in Asia or emerging markets to create a stronger safety profile for the U.S. approval application
Six Korean Cities Compete To Host Government Brain Research Center
SEOUL - South Korea's six big provincial cities, including Incheon near Seoul, are competing to win a huge contract that will cover the opening of the country's first government-sponsored brain research institute, which is likely to be surrounded by pharmaceutical, biologics and medical device companies